The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 5, 2007, Pages 377-383

  Horn, Leora ^a   Sandler, Alan B ^b   Putnam Jr , Joe B ^b   Johnson, David H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Non small cell lung cancer; Stage I non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; UFT; VINBLASTINE; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DEMENTIA; DIABETES MELLITUS; DISEASE SEVERITY; HEMIPLEGIA; HUMAN; KIDNEY DISEASE; LEUKEMIA; LIVER DISEASE; LUNG NON SMALL CELL CANCER; LYMPH NODE BIOPSY; LYMPHOMA; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY; VALIDATION PROCESS; ARTICLE; CANCER STAGING; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATHOLOGY; PATIENT SELECTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PROGNOSIS; SURVIVAL RATE;

EID: 34249855550     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000268669.64625.bb     Document Type: Note

References (63)

1. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005;23:3270-3278.
2. Solomon B, Mitchell JD, Bunn PA Jr. Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park) 2005;19:1685-1705.
3. Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant chemotherapy for early-stage non-small cell lung cancer. Chest 2005;128:2933-2943.
4. Tiseo M, Franciosi V, Grossi F, Ardizzoni A. Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice? Eur J Cancer 2006;42:8-16.
5. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
6. Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
7. Feld R, Rubinstein LV, Weisenberger TH. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984;2:1352-1358.
8. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22(14 Suppl):621s.
9. Strauss GM, Herndon J, Maddaus MA, et al. Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2006;24(18 Suppl):365s.
10. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-990.
11. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
12. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
13. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
14. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
15. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
16. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004;22:3860-3867.
17. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2006;24(18 Suppl):366s.
18. Sedrakyan A, van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2004;128:414-419.
19. Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study. Int J Cancer 2006;119:955-960.
20. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005;365:1308.
21. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med 2006;354:1667-1669.
22. Parker AB, Naylor CD. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J 2000;139:952.
23. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-98.
24. Mountain CF. Revisions in the International System for Staging Lung Cancer [see comments]. Chest 1997;111:1710-1717.
25. Mery CM, Pappas AN, Burt BM, et al. Diameter of non-small cell lung cancer correlates with long-term survival: implications for T stage. Chest 2005;128:3255-3260.
26. Carbone E, Asamura H, Takei H, et al. T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:907-912.
27. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000;117:374-379.
28. Lopez-Encuentra A, Duque-Medina JL, Rami-Porta R, de la Camara AG, Ferrando P. Staging in lung cancer: is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicenter study of 1,020 patients. Chest 2002;121:1515-1520.
29. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995;60:466-472.
30. Jones DR, Daniel TM, Denlinger CE, Rundall BK, Smolkin ME, Wick MR. Stage IB nonsmall cell lung cancers: are they all the same? Ann Thorac Surg 2006;81:1958-1962.
31. Kang J-H, Kim KD, Chung KY. Prognostic value of visceral pleura invasion in non-small cell lung cancer. Eur J Cardiothorac Surg 2003;23:865.
32. Manac'h D, Riquet M, Medioni J, Le Pimpec-Barthes F, Dujon A, Danel C. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg 2001;71:1088-1093.
33. Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-796.
34. Baylis F, Downie J. Professional recommendations: disclosing facts and values. J Med Ethics 2001;27:20-24.
35. Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer 2006;8:18-21.
36. Birim O, Kappetein AP, Takkenberg JJ, van Klaveren RJ, Bogers AJ. Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters. Ann Thorac Surg 2005;79:1137-1141.
37. Flieder DB, Port JL, Korst RJ, et al. Tumor size is a determinant of stage distribution in T1 non-small cell lung cancer. Chest 2005;128:2304-2308.
38. Greene FL, Page DL, Fleming ID, et al. (Eds.) AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.
39. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003;21:1029-1034.
40. Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur J Cardiothorac Surg 2005;27:680-685.
41. Ludwig MS, Goodman M, Miller DL, Johnstone PAS. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005;128:1545-1550.
42. Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-8712.
43. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 2006;24:3570-3575.
44. Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 2000;70:358-65; discussion 365-366.
45. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax 2006;61:597-603.
46. Sawyer TE, Bonner JA, Gould PM, Deschamps C, Lange CM, Li H. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys 1999;45:315-321.
47. Brechot JM, Chevret S, Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer 1996;78:2111-8.
48. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 1999;86:1976-1984.
49. Gabor S, Renner H, Popper H, et al. Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2004;25:439-442.
50. Onn A, Choe DH, Herbst RS, et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005;237:342-347.
51. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:1047-1057.
52. Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 2005;26:480-486.
53. Ambrogi V, Pompeo E, Elia S, Pistolese GR, Mineo TC. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur J Cardiothorac Surg 2003;23:811-817.
54. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2002;123:280-287.
55. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
56. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13:1539-1549.
57. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
58. Schabel FM. Rationale for adjuvant chemotherapy. Cancer 1977;39:2875-2882.
59. Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist 2006;11:111-125.
60. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
61. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-439.
62. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
63. Montgomery K. How Doctors Think: Clinical Judgment and the Practice of Medicine. New York: Oxford University Press, 2006.